Alliancebernstein L.P. cut its position in Aratana Therapeutics, Inc. (NASDAQ:PETX) by 84.4% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 39,150 shares of the biopharmaceutical company’s stock after selling 211,700 shares during the period. Alliancebernstein L.P. owned 0.10% of Aratana Therapeutics worth $207,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the company. Capital Fund Management S.A. acquired a new position in shares of Aratana Therapeutics during the first quarter worth about $282,000. Wells Fargo & Company MN boosted its position in shares of Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock worth $1,464,000 after buying an additional 203,738 shares in the last quarter. Cadence Capital Management LLC boosted its position in shares of Aratana Therapeutics by 21.7% in the first quarter. Cadence Capital Management LLC now owns 131,926 shares of the biopharmaceutical company’s stock worth $699,000 after buying an additional 23,506 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Aratana Therapeutics by 32.0% in the first quarter. Baird Financial Group Inc. now owns 40,758 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 9,880 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Aratana Therapeutics by 81.9% in the fourth quarter. AQR Capital Management LLC now owns 65,079 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 29,306 shares in the last quarter. 63.97% of the stock is currently owned by hedge funds and other institutional investors.
Aratana Therapeutics, Inc. (NASDAQ:PETX) traded up 0.18% during midday trading on Friday, hitting $5.48. The stock had a trading volume of 48,616 shares. Aratana Therapeutics, Inc. has a 52 week low of $4.97 and a 52 week high of $10.73. The company’s market cap is $235.65 million. The stock’s 50 day moving average price is $6.79 and its 200-day moving average price is $6.34.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. The firm had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.61 earnings per share. Equities research analysts predict that Aratana Therapeutics, Inc. will post ($1.07) earnings per share for the current year.
PETX has been the topic of a number of recent research reports. ValuEngine cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. Stifel Nicolaus cut their target price on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Aratana Therapeutics in a report on Friday, May 5th. BidaskClub cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Tuesday, July 4th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average price target of $9.50.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
